Canaan

Congratulations to the Sumble team! We’re proud to add Sumble to the Canaan portfolio and back founders Anthony Goldbloom and Ben Hamner as they build a breakthrough platform bringing context-driven AI to sales intelligence. Sumble is redefining how go-to-market teams discover and act on company and technology insights. Richard Boyle led our investment in Sumble. https://lnkd.in/gV4-BHvF

This weekend was a proud one for our team as we watched Vivace Therapeutics, Inc., a Canaan company that we have been working alongside since its inception, report an amazing data set for its lead program, VT3989, in treating #mesothelioma. The study results were featured in an oral presentation at the European Society for Medical Oncology (#ESMO) conference in Berlin and were concurrently published in Nature Medicine. Vivace's ongoing clinical trial of VT3989 demonstrated an overall response rate (ORR), a disease control rate (DCR), and progression-free survival (PFS) that far surpassed salvage chemotherapy benchmarks. Paired with an encouraging safety profile, these data support the advancement of VT3989 into a registrational Phase 3 study and suggest the potential for the drug to be the first new treatment approved for mesothelioma as its initial indication in more than 20 years. Vivace's story is one of ambition and impressive achievement. From setting out to develop a first-in-class drug against a completely novel #oncology target (#Hippo pathway) to working to bring a new therapy to patients with a notoriously difficult-to-treat #cancer type, the team has not shied away from the hardest of work that drug development has to offer. This past weekend represents a tremendous validation of the company's efforts to date, but there is still work to be done for patients with mesothelioma and their families. We look forward to continuing to stand with and support Vivace as it works to push VT3989 to the drug development finish line. Big shout out to Canaan’s own Tim Shannon, who is a founding member of the Vivace board. https://lnkd.in/ggivcV3N

Exciting news from our portfolio company Vivace Therapeutics, Inc. Therapeutics: Their experimental cancer drug VT3989 is showing real promise for mesothelioma patients who've already tried other treatments. In a recent study, nearly a third of patients saw their tumors shrink, and most patients saw their disease stabilize. These patients stayed progression-free for twice as long as with current standard treatments. The company plans to start a Phase 3 trial in early 2026—a critical step toward potential FDA approval. #Biotech #Oncology #Mesothelioma Tim Shannon https://lnkd.in/g4aPP9_9

Congratulations to the Arcade team on the addition of Varun Jampani as your Chief AI Officer! https://lnkd.in/gN8CARX8

Autonomous commerce is no longer science fiction—it's here. We're thrilled to have partnered with Motive Partners to bring together sharp operators from Stripe, Squarespace, and leading investors to discuss what this shift means for the industry.

Doorstep is transforming last-mile delivery tracking and solving this $4B issue faced by delivery companies. Congratulations to the Doorstep team on their $8M seed investment! We're thrilled to lead this round and have Hrach Simonian join their board. https://lnkd.in/gNgTe9GN

A big shout-out to the team at Alterome Therapeutics, Inc for being named one of the fiercest companies of 2025 by Fierce Biotech. As a Canaan portfolio company, we've seen the fierceness all along. It is how they've advanced two best-in-class cancer therapies from concept to clinic in just three and a half years. Congrats to CEO Jung Choi and the entire Alterome team on this well-deserved recognition. We can't wait to see what they do next.  Canaan's Uwe Schoenbeck is a member of the company's board. https://lnkd.in/guk9jqhM

@Glooko is making news this morning with its acquisition of Monarch Medical Technologies. The deal expands Glooko's capabilities into inpatient #insulin dosing and #glycemic management, complementing its strong foundation in the outpatient setting. CEO, Mike Alvarez, said Glooko is now positioned "to deliver a truly comprehensive hospital-to-home solution that can improve outcomes, streamline workflows, and enhance patient safety." We're proud to call Glooko a Canaan portfolio company and see the tremendous impact it is making in the lives of people with #diabetes. Canaan General Partner, Wende Hutton sits on the company's board. https://lnkd.in/g9FS2UGb

Exciting news from our cybersecurity ecosystem! Aim Security, founded by Matan G. and Adir G., has been acquired by Cato Networks in their first-ever acquisition. We're proud to have backed Aim Security. Aim Security distinguished itself early by recognizing that AI's unique attack vectors couldn't be addressed by retrofitting traditional security tools. Instead, they uniquely built solutions from the ground up to secure AI across all enterprise use cases. What makes Aim Security exceptional: - Elite founding team with deep experience from Google and Unit 8200 - Groundbreaking research capabilities - they discovered "EchoLeak," the first zero-click vulnerability in Microsoft 365 Copilot - Holistic platform securing AI applications you use, build, and run - Enterprise-grade solutions trusted by Fortune 500 companies This acquisition perfectly aligns two market leaders: Cato Networks's industry-leading SASE platform with Aim Security's cutting-edge AI security expertise. Together, they're positioned to secure the next wave of enterprise AI transformation. https://lnkd.in/erHnKmfN Joydeep Bhattacharyya #AISecurity #SASE #Enterprise #Cybersecurity #Investment

Congratulations Savvy on its acquisition by SailPoint! It was an exciting journey!Congrats to founders Guy Guzner Yoav Horman Eldar Kleiner David Ben Zakai ! Great to work with board partners Gili Raanan, Guru Chahal, Rene Bonvanie and Jim Routh… Canaan Howard Greenfield